Last week’s news that Amgen would uproot itself from Washington state – taking 660 jobs with it – was devastating to many in the Seattle biotech industry, particularly those who work there.
But it isn’t necessarily the referendum on this region’s ability to compete in the industry, according to at least one analyst.
“I think this is more company-specific,” said Jeff Loo, a health care equity research analyst at S&P Capital IQ. “I don’t think it’s a signal of what’s to come…
Last week’s news that Amgen would uproot itself from Washington state – taking 660 jobs with it – was devastating to many in the Seattle biotech industry, particularly those who work there.
But it isn’t necessarily the referendum on this region’s ability to compete in the industry, according to at least one analyst.
“I think this is more company-specific,” said Jeff Loo, a health care equity research analyst at S&P Capital IQ. “I don’t think it’s a signal of what’s to come…